Literature DB >> 8569181

Coexpression of platelet-derived growth factor alpha and beta receptors on medulloblastomas and other primitive neuroectodermal tumors is consistent with an immature stem cell and neuronal derivation.

A Smits1, D van Grieken, M Hartman, U Lendahl, K Funa, M Nistér.   

Abstract

Medulloblastomas and related childhood primitive neuroectodermal tumors (PNET) are currently thought to originate from a multipotent stem cell that can give rise to a variety of different tumor types, representing different lines of differentiation and stages of maturation of the original stem cell. The proliferation and differentiation of different cell types in the central nervous system are influenced by growth factors, such as platelet-derived growth factor (PDGF). In this study, we investigated the expression of the two types of PDGF receptors, alpha and beta, on 14 cases of PNET by immunohistochemistry and in situ hybridization. To characterize the tumor cells according to their differentiation and maturation, we performed immunohistochemistry with Ab against several members of the intermediate filament family, such as neurofilament, glial fibrillary acidic protein, vimentin, and the embryonal marker nestin. For the cerebral PNET, we found that the phenotype of multidirectional differentiation (with coexpression of neurofilament, glial fibrillary acidic protein, vimentin, and in some cases nestin) was associated with the expression of both PDGF alpha and beta receptors on the tumor cells. Medulloblastomas (i.e., cerebellar PNET), however, often showed the phenotype of partially committed neuron-like precursor cells, and this was associated with the predominant expression of PDGF alpha receptors on the tumor cells. Our findings show that the PDGF alpha receptor, previously known to play a role in the normal development of cells of the glial lineage, either exclusively or in combination with the PDGF beta receptor, is expressed on tumor cells of neuronal derivation. This "aberrant" expression of PDGF alpha receptors on PNET may reflect a feature of the malignant phenotype of these tumors. Further studies are needed to study the biologic effects of PDGF-A and its receptor in PNET.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8569181

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  14 in total

1.  Expression of the intermediate filament nestin in gastrointestinal stromal tumors and interstitial cells of Cajal.

Authors:  T Tsujimura; C Makiishi-Shimobayashi; J Lundkvist; U Lendahl; K Nakasho; A Sugihara; T Iwasaki; M Mano; N Yamada; K Yamashita; A Toyosaka; N Terada
Journal:  Am J Pathol       Date:  2001-03       Impact factor: 4.307

2.  A paediatric supratentorial primitive neuroectodermal tumour associated with malignant astrocytic transformation and a clonal origin of both components.

Authors:  Susanne A Kuhn; Uwe-Karsten Hanisch; Kristian Ebmeier; Christian Beetz; Michael Brodhun; Rupert Reichart; Christian Ewald; Thomas Deufel; Rolf Kalff
Journal:  Neurosurg Rev       Date:  2007-02-27       Impact factor: 3.042

Review 3.  Intermediate filaments in the nervous system: implications in cancer.

Authors:  C L Ho; R K Liem
Journal:  Cancer Metastasis Rev       Date:  1996-12       Impact factor: 9.264

Review 4.  Platelet-derived growth factor in human brain tumors.

Authors:  M Kirsch; J C Wilson; P Black
Journal:  J Neurooncol       Date:  1997-12       Impact factor: 4.130

5.  A PDGFRA promoter polymorphism, which disrupts the binding of ZNF148, is associated with primitive neuroectodermal tumours and ependymomas.

Authors:  C De Bustos; A Smits; B Strömberg; V P Collins; M Nistér; G Afink
Journal:  J Med Genet       Date:  2005-01       Impact factor: 6.318

6.  Gangliosides and neutral glycolipids in ependymal, neuronal and primitive neuroectodermal tumors.

Authors:  A J Yates; T K Franklin; P McKinney; R Collins; T Comas; C P Boesel; D K Pearl
Journal:  J Mol Neurosci       Date:  1999-04       Impact factor: 3.444

7.  Amplification and overexpression of KIT, PDGFRA, and VEGFR2 in medulloblastomas and primitive neuroectodermal tumors.

Authors:  Tea Blom; Annariikka Roselli; Valtteri Häyry; Olli Tynninen; Kirmo Wartiovaara; Miikka Korja; Kristiina Nordfors; Hannu Haapasalo; Nina N Nupponen
Journal:  J Neurooncol       Date:  2009-09-25       Impact factor: 4.130

8.  A novel role of HLA class I in the pathology of medulloblastoma.

Authors:  Courtney Smith; Mariarita Santi; Bhargavi Rajan; Elisabeth J Rushing; Mi Rim Choi; Brian R Rood; Robert Cornelison; Tobey J MacDonald; Stanislav Vukmanovic
Journal:  J Transl Med       Date:  2009-07-12       Impact factor: 5.531

9.  Cambogin is preferentially cytotoxic to cells expressing PDGFR.

Authors:  Ze Tian; Jie Shen; Fengfei Wang; Peigen Xiao; Junshan Yang; Hetian Lei; Andrius Kazlauskas; Isaac S Kohane; Erxi Wu
Journal:  PLoS One       Date:  2011-06-21       Impact factor: 3.240

10.  Nestin expression in osteosarcomas and derivation of nestin/CD133 positive osteosarcoma cell lines.

Authors:  Renata Veselska; Marketa Hermanova; Tomas Loja; Petr Chlapek; Iva Zambo; Karel Vesely; Karel Zitterbart; Jaroslav Sterba
Journal:  BMC Cancer       Date:  2008-10-16       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.